Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MAXY - Maxygen, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (260)	4/22/2010 4:12:31 AM
From: nigel bates	Read Replies (1) \| Respond to of 262

NEW YORK, April 21 (Reuters) - U.S. biotech company Codexis Inc priced shares in its initial public offering at the bottom of the expected range on Wednesday in its second attempt to list its shares for public trade. The Redwood City, California-based company sold 6 million shares for $13 each, raising about $78 million. It had planned to sell shares for between $13 and $15 each. Codexis sells enzymes and microbes modified to make industrial processes cleaner and faster. It also sells its "biocatalysts" to pharmaceutical companies including Merck & Co Inc , Pfizer Inc and Dr Reddy's Laboratories Ltd. It is also working with Royal Dutch Shell Plc on cellulosic biofuels -- biofuels that are made from plants like wheat straw. Total revenue rose more than 64 percent to $82.9 million in 2009. The company cut its losses 55 percent to $20.3 million in the same period. Codexis said in its prospectus that it does not expect to be profitable until at least 2011. Major shareholders in Codexis include funds associated with Maxygen Inc, Shell, the Singaporean government, CMEA Ventures, FirstMark Capital and Chevron Corp. Underwriters were led by Credit Suisse. The shares are expected to begin trading on the Nasdaq on Thursday under the symbol "CDXS."